Company Analysis
Sign in

Syndax Pharmaceuticals, Inc. (SNDX)

Nasdaq: SNDX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2007
Full chart Alerts Compare
Grade5.5
◀ Past 6.5● Present 4.5▶ Future 5.8
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

6 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Syndax Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
6
6 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 3 in 2024 and none in 2023
Applications published
30
5 of them in 2025
Names they are printed under
3
its own name
By yearGrantedApplications published
'08'09'10'12'13'14'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Syndax Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
18 published
Syndax Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
6 granted
11 published
Syndax Pharmaceuticals, Inc., a California Corporation its own name
US, as the owner printed on each patent
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 17, 202412,168,054Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibodyPharmaceuticalsSyndax Pharmaceuticals, Inc.
Jun 4, 202412,000,829Selection of patients for combination therapyPharmaceuticalsSyndax Pharmaceuticals, Inc.
Mar 5, 202411,919,901Inhibitors of the menin-MLL interactionPharmaceuticalsSyndax Pharmaceuticals, Inc.
Jul 26, 202211,397,184Selection of patients for combination therapyPharmaceuticalsSyndax Pharmaceuticals, Inc.
May 10, 202211,324,822Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancerPharmaceuticalsSyndax Pharmaceuticals, Inc.
Mar 12, 201910,226,472Methods for the treatment of breast cancerPharmaceuticalsSyndax Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0325664COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITORPharmaceuticalsSyndax Pharmaceuticals, Inc.
Sep 25, 20252025/0295661MENIN-MLL INHIBITORS FOR THE TREATMENT OF CANCEROrganic fine chemistrySyndax Pharmaceuticals, Inc.
May 29, 20252025/0170132SALTS AND POLYMORPHIC FORMS OF MENIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOFPharmaceuticalsSyndax Pharmaceuticals, Inc.
Feb 27, 20252025/0064925METHOD OF TREATING CANCER USING A COMBINATION OF ENTINOSTAT AND AN ANTI-CSF-1R ANTIBODYPharmaceuticalsSyndax Pharmaceuticals, Inc.
Jan 9, 20252025/0011441METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE-RELATED BRONCHIOLITIS OBLITERANS SYNDROME USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODYPharmaceuticalsSyndax Pharmaceuticals, Inc.
Dec 5, 20242024/0400564INHIBITORS OF THE MENIN-MLL INTERACTIONPharmaceuticalsSyndax Pharmaceuticals, Inc.
Dec 5, 20242024/0398944COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR TREATMENT OF CANCERPharmaceuticalsSyndax Pharmaceuticals, Inc.
Aug 29, 20242024/0288425SELECTION OF PATIENTS FOR COMBINATION THERAPYPharmaceuticalsSyndax Pharmaceuticals, Inc.
Jul 18, 20242024/0238291COMBINATIONS FOR TREATMENT OF CANCERPharmaceuticalsSyndax Pharmaceuticals, Inc.
Jun 1, 20232023/0165858COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOFPharmaceuticalsSyndax Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SNDX · research, not advice